Literature DB >> 21988997

Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question.

Thomas J Hope1.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21988997     DOI： 10.1038/nm.2528

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  14 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

2.  Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.

Authors:  Wanliang Shi; Xuelian Zhang; Xin Jiang; Haiming Yuan; Jong Seok Lee; Clifton E Barry; Honghai Wang; Wenhong Zhang; Ying Zhang
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

3.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

4.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.

Authors:  Hugo Mouquet; Johannes F Scheid; Markus J Zoller; Michelle Krogsgaard; Rene G Ott; Shetha Shukair; Maxim N Artyomov; John Pietzsch; Mark Connors; Florencia Pereyra; Bruce D Walker; David D Ho; Patrick C Wilson; Michael S Seaman; Herman N Eisen; Arup K Chakraborty; Thomas J Hope; Jeffrey V Ravetch; Hedda Wardemann; Michel C Nussenzweig
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

5.  HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.

Authors:  Troy J Kemp; Allan Hildesheim; Mahboobeh Safaeian; Joseph G Dauner; Yuanji Pan; Carolina Porras; John T Schiller; Douglas R Lowy; Rolando Herrero; Ligia A Pinto
Journal:  Vaccine       Date:  2011-01-15       Impact factor: 3.641

6.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

7.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

8.  Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.

Authors:  E A Emini; W A Schleif; J H Nunberg; A J Conley; Y Eda; S Tokiyoshi; S D Putney; S Matsushita; K E Cobb; C M Jett
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

9.  Characteristics of the earliest cross-neutralizing antibody response to HIV-1.

Authors:  Iliyana Mikell; D Noah Sather; Spyros A Kalams; Marcus Altfeld; Galit Alter; Leonidas Stamatatos
Journal:  PLoS Pathog       Date:  2011-01-13       Impact factor: 6.823

10.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962
View more
  23 in total

1.  Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.

Authors:  Shari N Gordon; Melvin N Doster; Rhonda C Kines; Brandon F Keele; Egidio Brocca-Cofano; Yongjun Guan; Poonam Pegu; Namal P M Liyanage; Monica Vaccari; Nicolas Cuburu; Christopher B Buck; Guido Ferrari; David Montefiori; Michael Piatak; Jeffrey D Lifson; Anastasia M Xenophontos; David Venzon; Marjorie Robert-Guroff; Barney S Graham; Douglas R Lowy; John T Schiller; Genoveffa Franchini
Journal:  J Immunol       Date:  2014-11-14       Impact factor: 5.422

2.  HIV-1 Env antibodies: are we in a bind or going blind?

Authors:  John P Moore
Journal:  Nat Med       Date:  2012-03-06       Impact factor: 53.440

3.  A mouse model for HIV-1 entry.

Authors:  John Pietzsch; Henning Gruell; Stylianos Bournazos; Bridget M Donovan; Florian Klein; Ron Diskin; Michael S Seaman; Pamela J Bjorkman; Jeffrey V Ravetch; Alexander Ploss; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

4.  Predicting first traversal times for virions and nanoparticles in mucus with slowed diffusion.

Authors:  Austen M Erickson; Bruce I Henry; John M Murray; Per Johan Klasse; Christopher N Angstmann
Journal:  Biophys J       Date:  2015-07-07       Impact factor: 4.033

5.  Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity.

Authors:  Pinghuang Liu; Latonya D Williams; Xiaoying Shen; Mattia Bonsignori; Nathan A Vandergrift; R Glenn Overman; M Anthony Moody; Hua-Xin Liao; Daniel J Stieh; Kerrie L McCotter; Audrey L French; Thomas J Hope; Robin Shattock; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

6.  A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities.

Authors:  Jeffrey R Schneider; Xiaoying Shen; Chiara Orlandi; Tinashe Nyanhete; Sheetal Sawant; Ann M Carias; Archer D Smith; Neil L Kelleher; Ronald S Veazey; George K Lewis; Georgia D Tomaras; Thomas J Hope
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

Review 7.  Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Authors:  Jean-Louis Excler; Julie Ake; Merlin L Robb; Jerome H Kim; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2014-06-11

8.  Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.

Authors:  S Moses Dennison; Kara M Anasti; Frederick H Jaeger; Shelley M Stewart; Justin Pollara; Pinghuang Liu; Erika L Kunz; Ruijun Zhang; Nathan Vandergrift; Sallie Permar; Guido Ferrari; Georgia D Tomaras; Mattia Bonsignori; Nelson L Michael; Jerome H Kim; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Hua-Xin Liao; Barton F Haynes; S Munir Alam
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

9.  Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry.

Authors:  Qingsheng Li; Ming Zeng; Lijie Duan; James E Voss; Anthony J Smith; Stefan Pambuccian; Liang Shang; Stephen Wietgrefe; Peter J Southern; Cavan S Reilly; Pamela J Skinner; Mary L Zupancic; John V Carlis; Michael Piatak; Diane Waterman; R Keith Reeves; Katherine Masek-Hammerman; Cynthia A Derdeyn; Michael D Alpert; David T Evans; Heinz Kohler; Sybille Müller; James Robinson; Jeffrey D Lifson; Dennis R Burton; R Paul Johnson; Ashley T Haase
Journal:  J Immunol       Date:  2014-08-18       Impact factor: 5.422

10.  Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.

Authors:  Bin Su; Maryse Peressin; Camille Ducloy; Julien Penichon; Luzia M Mayr; Géraldine Laumond; Sylvie Schmidt; Thomas Decoville; Christiane Moog
Journal:  AIDS Res Hum Retroviruses       Date:  2015-09-10       Impact factor: 2.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.